A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma
Status:
Recruiting
Trial end date:
2022-08-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety, tolerability, DLTs, MTD, and preliminary anti tumor
activity of tivozanib in combination with durvalumab in subjects with advanced HCC.